BASF Raises Acquisition Offer for Evonik Industries, Shares Jump 5.2%

The Quick Take

• BASF has raised its acquisition offer for Evonik Industries, sending EVKIY ADR shares up 5.2% as markets price in increased deal completion probability.
• The revised bid represents a strategic push by BASF to consolidate specialty chemicals capacity at a time when European chemical sector consolidation is accelerating under cost and competitive pressure.
• Evonik shareholders now face a classic M&A arbitrage situation: the raised offer narrows the spread but retains regulatory and financing risk premium.

BASF has raised its acquisition offer for Evonik Industries, triggering a 5.2% move in Evonik's EVKIY American depositary receipts as merger arbitrage traders reduced the discount between the current trading price and the revised bid value. The deal would create one of Europe's largest specialty chemicals combinations, consolidating Evonik's performance materials, nutrition and care, and smart materials divisions with BASF's existing specialty chemicals platform. European chemical sector consolidation has intensified as energy cost pressures, Chinese competition in commodity chemicals, and the capital intensity of green chemistry transitions have made scale and portfolio breadth more important competitive advantages than at any point in the last two decades.

For BASF, the raised offer signals management conviction that the strategic rationale justifies the increased acquisition premium — likely reflecting a competitive bid dynamic or a negotiation from Evonik's supervisory board for improved terms. Evonik shareholders including RAG-Stiftung (the foundation holding approximately 59% of Evonik) would need to approve the transaction, making the foundation's stance the pivotal variable in deal completion. A successful transaction would allow BASF to accelerate its portfolio rebalancing away from commodity petrochemicals toward higher-margin specialty applications in nutrition, electronics, and sustainable materials — all growth segments attracting premium valuations in the current market.

Forward signals include the regulatory review timeline from the European Commission's merger control division, which will assess market concentration in specific specialty chemistry sub-segments where BASF and Evonik have overlapping product lines. The RAG-Stiftung's official response to the raised offer will determine whether a formal acceptance process begins. Investors in the merger arbitrage spread should track the spread relative to comparable European chemical M&A precedent to assess whether the current discount compensates adequately for completion risk.